公开(公告)号：US20130079303A1

公开(公告)日：2013-03-28

申请号：US13681230

申请日：2012-11-19

Applicant: Amgen Inc.

Inventor： Kristin L. ANDREWS ,  Yunxin Y. Bo ,  Shon Booker ,  Victor J. Cee ,  Noel D'Angelo ,  Bradley J. Herberich ,  Fang-Tsao Hong ,  Claire I.M. Jackson ,  Brian Alan Lanman ,  Hongyu Liao ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian Leonard Smith ,  Seifu Tadesse ,  Nuria A. Tamayo ,  Bin Wu ,  Ryan Wurz ,  Kevin C. Yang

IPC: C07D473/00 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/14

CPC classification number: C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。

公开(公告)号：US11905281B2

公开(公告)日：2024-02-20

申请号：US17031607

申请日：2020-09-24

Applicant: Amgen Inc.

Inventor： Brian Alan Lanman ,  Jian Chen ,  Anthony B. Reed ,  Victor J. Cee ,  Longbin Liu ,  David John Kopecky ,  Patricia Lopez ,  Ryan Paul Wurz ,  Thomas T. Nguyen ,  Shon Booker ,  Nobuko Nishimura ,  Youngsook Shin ,  Nuria A. Tamayo ,  John Gordon Allen ,  Jennifer Rebecca Allen

IPC: C07D471/04 ,  C07D213/82 ,  C07D417/04 ,  A61K38/07 ,  C07D487/08 ,  C07D417/12 ,  C07D513/04 ,  C07D487/10 ,  C07D487/04 ,  C07D401/04 ,  C07D239/80 ,  C07D401/14 ,  C07D237/34 ,  C07D403/04 ,  A61K31/496 ,  A61K31/416 ,  A61K31/55 ,  A61K31/454 ,  A61K31/519 ,  A61K31/502 ,  A61K31/517 ,  A61K31/5025 ,  A61P35/00 ,  A61K31/7068 ,  C07D275/04 ,  C07D475/00

CPC classification number: C07D417/04 ,  A61K31/416 ,  A61K31/454 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/7068 ,  A61K38/07 ,  A61P35/00 ,  C07D237/34 ,  C07D239/80 ,  C07D275/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D417/12 ,  C07D471/04 ,  C07D475/00 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D513/04

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US11845760B2

公开(公告)日：2023-12-19

申请号：US17552016

申请日：2021-12-15

Applicant: AMGEN INC.

Inventor： Shon Booker ,  Matthew Paul Bourbeau ,  John R. Butler ,  Sanne Ormholt Schroder Glad ,  Brian Alan Lanman ,  Patricia Lopez ,  Francesco Manoni ,  Liping H. Pettus ,  Ian Sarvary ,  Nuria A. Tamayo ,  Mikkel Vestergaard ,  Nicholas Anthony Weires

IPC: C07D471/04 ,  C07D471/14 ,  C07D491/04 ,  C07D491/14 ,  C07D495/04 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61P35/00 ,  C07D491/06 ,  C07D471/06 ,  C07D471/16 ,  C07D491/16

CPC classification number: C07D491/06 ,  A61P35/00 ,  C07D471/06 ,  C07D471/16 ,  C07D491/16

Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:

公开(公告)号：US08772480B2

公开(公告)日：2014-07-08

申请号：US13681230

申请日：2012-11-19

Applicant: Amgen Inc.

Inventor： Kristin L. Andrews ,  Yunxin Y. Bo ,  Shon Booker ,  Victor J. Cee ,  Noel D'Angelo ,  Bradley J. Herberich ,  Fang-Tsao Hong ,  Claire L. M. Jackson ,  Brian Alan Lanman ,  Hongyu Liao ,  Longbin Liu ,  Nobuko Nishimura ,  Mark H. Norman ,  Liping H. Pettus ,  Anthony B. Reed ,  Adrian Leonard Smith ,  Seifu Tadesse ,  Nuria A. Tamayo ,  Bin Wu ,  Ryan Wurz ,  Kevin C. Yang

IPC: C07D401/04 ,  C07D401/14 ,  A61K31/444 ,  A61K31/53 ,  A61P35/00

CPC classification number: C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的盐; 使用该化合物治疗疾病或病症如癌症的方法; 和含有这些化合物的药物组合物，其中变量如本文所定义。